Bessemer Group’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$747K Buy
3,816
+732
+24% +$142K ﹤0.01% 1021
2025
Q4
$535K Sell
3,084
-1
-0% -$182 ﹤0.01% 1117
2025
Q3
$588K Buy
3,085
+190
+7% +$33.7K ﹤0.01% 805
2025
Q2
$519K Sell
2,895
-4,726
-62% -$821K ﹤0.01% 802
2025
Q1
$1.29M Sell
7,621
-13,190
-63% -$2.17M ﹤0.01% 601
2024
Q4
$3.14M Buy
20,811
+65
+0.3% +$10.1K 0.01% 550
2024
Q3
$3.22M Buy
20,746
+19,242
+1,279% +$2.87M 0.01% 561
2024
Q2
$206K Sell
1,504
-658,979
-100% -$90.2M ﹤0.01% 1008
2024
Q1
$87.9M Sell
660,483
-238,118
-26% -$30.9M 0.16% 154
2023
Q4
$124M Sell
898,601
-5,270
-0.6% -$693K 0.24% 115
2023
Q3
$110M Sell
903,871
-2,730
-0.3% -$364K 0.24% 117
2023
Q2
$127M Buy
906,601
+3,520
+0.4% +$485K 0.27% 102
2023
Q1
$128M Buy
903,081
+164,077
+22% +$23.5M 0.3% 101
2022
Q4
$116M Buy
739,004
+8,208
+1% +$1.18M 0.28% 111
2022
Q3
$89.7M Buy
730,796
+8,311
+1% +$1.09M 0.23% 126
2022
Q2
$96.1M Buy
722,485
+15,367
+2% +$2.09M 0.24% 125
2022
Q1
$96.8M Buy
707,118
+8,299
+1% +$1.16M 0.2% 145
2021
Q4
$121M Buy
698,819
+16,183
+2% +$2.46M 0.24% 127
2021
Q3
$99.2M Buy
682,636
+6,198
+0.9% +$907K 0.21% 151
2021
Q2
$89.3M Buy
676,438
+28,417
+4% +$3.72M 0.19% 154
2021
Q1
$83.2M Buy
648,021
+48,439
+8% +$5.97M 0.2% 149
2020
Q4
$71.5M Sell
599,582
-75,026
-11% -$9.15M 0.19% 144
2020
Q3
$77.2M Sell
674,608
-303,621
-31% -$35.9M 0.23% 117
2020
Q2
$111M Buy
978,229
+14,182
+1% +$1.5M 0.35% 81
2020
Q1
$77.4M Sell
964,047
-322,281
-25% -$33.4M 0.31% 94
2019
Q4
$137M Buy
1,286,328
+511,512
+66% +$53.3M 0.44% 65
2019
Q3
$82.9M Buy
774,816
+3,905
+0.5% +$401K 0.3% 101
2019
Q2
$78.5M Buy
770,911
+33,153
+4% +$3.19M 0.26% 116
2019
Q1
$66.3M Buy
737,758
+73,604
+11% +$6.38M 0.25% 121
2018
Q4
$55.3M Sell
664,154
-1,285,535
-66% -$121M 0.24% 119
2018
Q3
$210M Sell
1,949,689
-19,873
-1% -$2.18M 0.78% 42
2018
Q2
$217M Sell
1,969,562
-1,088
-0.1% -$113K 0.84% 41
2018
Q1
$198M Sell
1,970,650
-137,146
-7% -$14M 0.77% 44
2017
Q4
$208M Buy
2,107,796
+889,802
+73% +$84.4M 0.81% 45
2017
Q3
$114M Sell
1,217,994
-742,492
-38% -$78.8M 0.46% 84
2017
Q2
$218M Sell
1,960,486
-498,768
-20% -$52.7M 0.88% 34
2017
Q1
$241M Buy
2,459,254
+52,036
+2% +$4.96M 1.01% 24
2016
Q4
$221M Buy
2,407,218
+313,930
+15% +$27.1M 1.02% 15
2016
Q3
$177M Buy
2,093,288
+170,210
+9% +$14.3M 0.89% 26
2016
Q2
$157M Buy
1,923,078
+149,744
+8% +$11.4M 0.86% 28
2016
Q1
$127M Sell
1,773,334
-1,231
-0.1% -$82.6K 0.72% 37
2015
Q4
$126M Buy
1,774,565
+1,719,687
+3,134% +$116M 0.7% 46
2015
Q3
$3.37M Sell
54,878
-49
-0.1% -$3.42K 0.02% 322
2015
Q2
$3.98M Buy
54,927
+25,009
+84% +$1.85M 0.02% 312
2015
Q1
$2.3M Buy
29,918
+7,168
+32% +$513K 0.01% 373
2014
Q4
$1.53M Buy
22,750
+4,000
+21% +$252K 0.01% 419
2014
Q3
$1.14M Buy
18,750
+18,700
+37,400% +$1.15M 0.01% 438
2014
Q2
$3K Hold
50
﹤0.01% 1212
2014
Q1
$3K Sell
50
-787,715
-100% -$42.2M ﹤0.01% 1217
2013
Q4
$42.2M Buy
787,765
+525,715
+201% +$31.2M 0.3% 115
2013
Q3
$16.2M Buy
262,050
+262,000
+524,000% +$15.7M 0.13% 132
2013
Q2
$3K Buy
+50
New +$2.98K ﹤0.01% 1208

Other funds holding DGX

Bessemer Group's DGX Position: Q1 2026 in Review

Bessemer Group increased its Quest Diagnostics (DGX) stake by 24% in Q1 2026, buying an estimated $142K and bringing the position to 3,816 shares worth $747K. The position accounts for ﹤0.01% of the portfolio, ranked #1021.

Bessemer Group first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $241M in Q1 2017. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Bessemer Group held 3,816 shares of Quest Diagnostics worth $747K as of Q1 2026.
  • Bessemer Group bought 732 Quest Diagnostics shares in Q1 2026, an estimated $142K.
  • Quest Diagnostics made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #1021 holding.
  • Bessemer Group first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
  • Bessemer Group's Quest Diagnostics position peaked at $241M in Q1 2017.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.